This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Theses and Dissertations
This collection contains theses and dissertations of graduate students of the University of Alberta. The collection contains a very large number of theses electronically available that were granted from 1947 to 2009, 90% of theses granted from 2009-2014, and 100% of theses granted from April 2014 to the present (as long as the theses are not under temporary embargo by agreement with the Faculty of Graduate and Postdoctoral Studies). IMPORTANT NOTE: To conduct a comprehensive search of all UofA theses granted and in University of Alberta Libraries collections, search the library catalogue at www.library.ualberta.ca - you may search by Author, Title, Keyword, or search by Department.
To retrieve all theses and dissertations associated with a specific department from the library catalogue, choose 'Advanced' and keyword search "university of alberta dept of english" OR "university of alberta department of english" (for example). Past graduates who wish to have their thesis or dissertation added to this collection can contact us at erahelp@ualberta.ca.
Items in this Collection
- 10Cytochrome P450
- 4Cardiac hypertrophy
- 2Arachidonic Acid
- 2Arachidonic acid
- 2Aryl hydrocarbon receptor
- 2Epoxyeicosatrienoic acids
- 1Althurwi, Hassan N
- 1Asghar, Muhammad Waheed
- 1Chaudhary, Ketul R
- 1El-Sherbeni, Ahmed Abd El-Hakeem
- 1ElKhatib, Mohammed
- 1Elghiaty, Mahmoud AA
- 3El-Kadi, Ayman (Faculty of Pharmacy and Pharmaceutical Sciences)
- 2El-Kadi, Ayman (Pharmacy & Pharmaceutical Sciences)
- 1Ayman, El-Kadi (Pharmacy and Pharmaceutical Sciences)
- 1Brocks, Dion (Pharmacy and Pharmaceutical Sciences)
- 1El-Kadi, Ayman (Faculty of pharmacy and pharmaceutical sciences)
- 1El-Kadi, Ayman (Pharmacy and Pharmaceutical Sciences)
-
Effects of Inflammation and Non-Steroidal Anti-Inflammatory Drugs on Renin-Angiotensin System and Cytochrome P450 Metabolites of Arachidonic Acid
DownloadSpring 2016
Patients suffering from inflammatory disorders are at higher risk of cardiovascular (CV) morbidity and mortality compared to general population. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat pain and inflammation associated with inflammatory disorders such as rheumatoid...
-
Fall 2012
Ischemic heart disease remains a major cause of illness, disability and death worldwide, as such there remains a need for novel pharmacological agents that protect against myocardial ischemia reperfusion (I/R) injury. Epoxyeicosatrienoic acids (EETs) are cytochrome P450 (CYP) epoxygenase...
-
MODULATING CYTOCHROME P450-MEDIATED ARACHIDONIC ACID METABOLISM AS A POTENTIAL NEW TREATMENT MODALITY FOR CARDIAC HYPERTROPHY
DownloadSpring 2017
El-Sherbeni, Ahmed Abd El-Hakeem
Arachidonic acid (AA) metabolism has long been a very appealing target for drug discovery and development efforts. Beside cyclooxygenase and lipoxygenase pathways, AA is also metabolized by the recently recognized cytochrome P450 (P450) pathway, forming several biologically-active...
-
MODULATION OF ARYL HYDROCARBON RECEPTOR (AHR)-REGULATED CARCINOGEN ACTIVATING ENZYMES BY ORGANIC ARSENICALS: A POTENTIAL THERAPEUTIC TARGET
DownloadSpring 2017
Arsenic is a worldwide environmental pollutant that is associated with skin and several types of internal cancers, such as liver, lung, kidney, urinary bladder, and prostate cancers. Recent reports revealed that organic arsenic metabolites, such as trimethylarsine oxide (TMAO), dimethylarsinic...
-
Modulation of Aryl Hydrocarbon Receptor (AHR)-Regulated Metabolic Enzymes by Arsenic Trioxide and its Thioarsenical Metabolite
DownloadFall 2024
Arsenic trioxide (ATOIII) has evolved into a successful therapy for acute promyelocytic leukemia (APL), however, being an arsenical, it retains at its core the hypertoxic characteristics of that notorious metalloid. Such inherent toxicity causes a constellation of complications in APL patients,...
-
Spring 2024
Heart failure (HF) is typically preceded by cardiac hypertrophy (CH), which is characterized by cardiomyocytic enlargement following stress. During CH development, expression of cytochrome P450 enzymes (CYPs) and metabolism of arachidonic acid (AA) are altered. Cardiac CYPs metabolize AA into...
-
The role of cytochrome P450 and the protective effect of EETs against isoproterenol-induced cellular hypertrophy in rat H9c2 cell line
DownloadSpring 2013
Cytochrome P450 (CYP) enzymes have been identified in the heart and their levels have been reported to be altered during cardiac hypertrophy and heart failure. Furthermore, CYP enzymes have been shown to metabolize arachidonic acid to cardioprotective epoxyeicosatrienoic acids (EETs) and...
-
THE ROLE OF CYTOCHROME P450 AND THEIR ASSOCIATED ARACHIDONIC ACID METABOLITES IN THE INITIATION AND PROGRESSION OF CARDIAC HYPERTROPHY
DownloadSpring 2016
Heart failure (HF) is the leading cause of mortality and disability in adults worldwide. Cardiac hypertrophy is an independent risk factor and one of the major hallmarks of HF. Research in cardiac hypertrophy is considered as a research into the early events in the development of HF. The...
-
The role of cytochrome P450 derived arachidonic acid metabolites against Angiotensin II-induced cardiac hypertrophy in Sprague Dawley rats and the RL-14 cell line
DownloadFall 2015
Several cytochrome P450 (CYP) enzymes and their arachidonic acid (AA) metabolites play essential roles in the maintenance of cardiovascular health, and their alteration gives rise to a number of cardiovascular diseases, including cardiac hypertrophy and heart failure. Recent data demonstrated...
-
The Role of Subterminal Hydroxyeicosatetraenoic Acids in the Pathogenesis of Cardiac Hypertrophy
DownloadFall 2021
Cardiac hypertrophy is a complex condition which is characterized by increased mass of the heart muscle. If untreated, cardiac hypertrophy can ultimately lead to heart failure (HF), arrhythmia and sudden death. Accumulating evidence suggest that pathological cardiac hypertrophy is strongly...